MUC1 and ovarian carcinoma: However, clinical results from a Phase I clinical trial including 25 patients with CEA- or MUC1-expressing metastatic cancers who had progressive disease following standard chemotherapy (three of them with ovarian cancer) showed limited evidence of clinical activity [53].